Viscous Nasal Cannabinoid Compositions Bypass Hepatic First-Pass Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current administration methods for cannabinoids, such as CBD, suffer from low bioavailability, hepatic first-pass metabolism, and undesirable side effects, making them inconvenient and less effective for treating conditions like schizophrenia and epilepsy.
Innovation Solution
Development of nasal cannabinoid pharmaceutical compositions, specifically semi-solid or viscous liquid formulations, for intranasal administration that deposit cannabinoids directly onto the nasal mucosa, avoiding hepatic metabolism and providing rapid systemic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids are administered orally or through conventional methods, then they can be delivered to the subject, but bioavailability is low and hepatic first-pass metabolism occurs
Solution Approach 1:
The nasal cavity serves as an intermediary route of administration, allowing cannabinoids to be absorbed through the nasal mucosa and enter the systemic circulation directly, bypassing the gastrointestinal tract and liver metabolism. This mediator route eliminates first-pass metabolism and significantly improves bioavailability.
Solution Approach 2:
The invention transitions from conventional oral or systemic administration routes to a topical nasal application dimension. By applying the composition locally to the nasal mucosa, the drug enters the bloodstream through a different anatomical dimension, avoiding hepatic metabolism and achieving rapid systemic delivery.
2Ease of manufacture
If conventional cannabinoid administration methods are used, then treatment can be provided, but undesirable side effects occur
Solution Approach 1:
The invention changes the administration parameter from oral or systemic delivery to topical nasal application. This parameter change allows for controlled local absorption through the nasal mucosa, providing therapeutic effects while minimizing systemic side effects associated with conventional administration methods.
Solution Approach 2:
The composition is applied locally to the nasal mucosa, which has high vascularity and absorption capacity. This local application allows the cannabinoids to be absorbed directly into the bloodstream at the site of administration, providing efficient delivery with reduced side effects compared to oral or inhalation methods.
3Speed
If rapid delivery of cannabinoids is achieved through nasal administration, then bioavailability improves, but the composition must be in a suitable semi-solid or viscous liquid form
Solution Approach 1:
The invention changes the physical state parameter of the cannabinoid composition from solid or simple liquid to semi-solid or viscous liquid form. This formulation change allows the composition to remain stable, adhere to the nasal mucosa, and facilitate controlled absorption while achieving rapid systemic delivery.
Solution Approach 2:
The composition comprises cannabinoids combined with carrier materials in a semi-solid or viscous liquid matrix. This composite formulation provides structural stability, controlled release properties, and appropriate viscosity for nasal application, balancing formulation complexity with rapid delivery effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nasal compositions achieve rapid and sustained plasma levels of cannabinoids, improving bioavailability and reducing side effects, offering a convenient, discreet, and effective treatment for conditions like schizophrenia, epilepsy, and other disorders.
Implementation Method 1
deposit cannabinoids directly onto the nasal mucosa, avoiding hepatic metabolism and providing rapid systemic delivery
Data Source
AI summary
A nasally administered cannabinoid semi-solid or viscous liquid composition; nasal methods for administering the nasal pharmaceutical compositions; methods for manufacturing the nasal pharmaceutical compositions; and nasal methods of treating diseases treatable by the nasal pharmaceutical compositions formulated with a cannabinoid or mixtures thereof.